Clover Pharmaceuticals Debuts in Hong Kong, raises $260 million
Investing.com
Published Nov 05, 2021 12:26AM ET
By Gina Lee
Investing.com – Clover Biopharmaceuticals Ltd. (HK:2197) made its debut on the Hong Kong Stock Exchange on Friday, raising HK$2.03 billion ($260.17 million) in the process.
Shares were steady at HK$13 ($1.67) as of 12:25 AM ET (4:25 AM GMT), after trading as high as HK$13.56 earlier in the session.
Goldman Sachs (NYSE:GS) (Asia) LLC, China International Capital Corporation Hong Kong Securities Limited, and Credit Suisse (SIX:CSGN) (Hong Kong) Limited participated as joint global coordinators.
The COVID-19 vaccine developer priced the 150 million shares on offer at HK$13.38, the upper part of its HK$12.80 to HK$13.50 price guidance range. There is also an over-allocation of 22,500,000 Offer shares in the international offering.
Based on the offer price, the net proceeds from the listing, after deducting underwriting fees and other expenses, are estimated to be roughly HK$1.87 billion, or $240.26 million, according to the company. The bulk of the proceeds will be used in the research, production, and commercialization of its core products.
The company’s core product includes S-Trimer (SCB-2019), its protein-based COVID-19 vaccine candidate. A large global clinical trial showed that S-Trimer was 67% effective against COVID-19 of any degree of severity, and 79% against the Delta variant, the company said in September.
Clover has also inked a deal to supply up to 414 million doses of its COVID-19 vaccine through the global vaccine sharing scheme COVAX.
“We are excited at what the future holds as we submit conditional regulatory approval applications for and potentially commercialize S-Trimer in the near term,” Joshua Liang, CEO and executive director at Clover, said in a statement.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.